Rakuten Medical



Hiroyuki Kodama, Ph.D.

Chief Product Officer,
Rakuten Medical, Inc.

Representative Director and President,
Rakuten Medical K.K.

Managing Director, Medlight SA

As Chief Product Officer for Rakuten Medical, Hiro oversees all aspects of global device operations, including engineering, development, manufacturing, and quality assurance. Hiro is also responsible for product strategy, commercialization, marketing, and product lifecycle management for the Alluminox® platform-based photoimmunotherapy.

Since joining Rakuten Medical in 2019, Hiro has advanced strategic collaborations with academia and medical device companies. In 2020, he led the acquisition of Medlight SA, a Swiss-based medical device company, bringing critical device development and manufacturing capabilities in-house and strengthening the technological foundation for global expansion.

As President of Rakuten Medical K.K., Hiro oversees all aspects of the company's operations in Japan, the only market where Alluminox platform-based photoimmunotherapy has been commercialized. Since assuming the role in August 2024, he has led efforts to ensure the stable supply of high-quality products and strengthen the infrastructure required for the safe and appropriate delivery of treatment. Leveraging real-world clinical insights generated in Japan, Hiro also supports commercialization preparations and readiness in markets around the world to expand patient access to Alluminox platform-based photoimmunotherapy for patients globally.

Prior to joining Rakuten Medical, Hiro was a consultant focusing mainly on the healthcare sector at McKinsey & Company; conducted research at Kyoto University's institute for Integrated Cell-Material Sciences (iCeMS) as post-doctoral fellow; and engaged in pharmaceutical and medical device business operations at Mitsui & Co., Ltd., one facet of which included life sciences investment through NovaQuest Capital Management.

Hiro received a bachelor's degree in engineering from the Tokyo Institute of Technology (now Institute of Science Tokyo), and a Ph.D. in Molecular Biology from the University of Tokyo for his research on translation mechanisms of human genetic information. He earned an MBA from the University of Oxford.

October 2026